Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Study objectives and endpoints

From: Platelet-rich plasma in Achilles tendon healing 2 (PATH-2) trial: statistical analysis plan for a multicentre, double-blinded, parallel-group, placebo-controlled randomised clinical trial

Objectives Endpoints
• Evaluate the clinical efficacy of platelet-rich plasma (PRP) in acute Achilles tendon rupture (ATR) recovery in terms of muscle-tendon function
At 24 weeks post treatment:
• Limb Symmetry Index of work capacity during heel-rise endurance test (HRET); maximum heel-rise height and repetitions during HRET will be reported as secondary outcomes
• Evaluate the clinical efficacy of PRP in acute ATR in terms of participant-reported functional recovery, pain and quality of life
During the first 2 weeks post treatment:
• Visual analogue scale pain daily diary [15]
At 4, 7, 13 and 24 weeks post treatment:
• Achilles Tendon Rupture Score [16]
• Patient-Specific Functional Scale [17, 18]
• SF-12 (acute) [19]
Exploratory (sub-studies):
• Determine the key components of PRP that contribute to its mechanism of action
• Further understand, in an immunohistochemical sub-study, the mechanisms of PRP that may account for its clinical efficacy
• Identify the histological pathways that PRP may alter to exert its effects; using these results and those from the PRP biological component sub-study, inform future targeted manipulation of PRP properties to maximise its efficacy in tendon healing
At baseline (sub-study 1)
• Blood sample for PRP component analysis (cell count, relevant tendon active growth factors, concentrations and platelet activation); all PRP group participants
• Whole blood analysis for cell count and concentrations; all participants.
At 6 weeks post treatment (sub-study 2):
• A needle biopsy of the healing Achilles tendon under ultrasound guidance during an outpatient visit for immunohistochemistry analysis (n = 16)